23rd International Mammalian Genome Conference: 1 - 4 November 2009, Hilton La Jolla Torrey Pines, California.

Conference Speakers

To view Speaker Preview information please click here.

Keynote speakers will include: David Adams, Ph.D. (Wellcome Trust Sanger Institute, UK); Steve Barthold, DVM, Ph.D. (School of Veterinary Medicine University of California, USA); Bruce Beutler, M.D. (The Scripps Research Institute, USA); Steve Brown, Ph.D. (Harwell Science and Innovation Campus, UK); Catherine Dulac, Ph.D. (Harvard University, USA); Janan Eppig, Ph.D. (The Jackson Laboratory, USA); Ron Evans, Ph.D. (The Salk Institute, USA); Colin Fletcher, Ph.D. (National Human Genome Research Institute National Institutes of Health, USA); Chris Goodnow, Ph.D. (Australian Cancer Research Foundation Genetics Laboratory and Medical Genome Centre,John Curtin School of Medical Research, Australian National University, Australia); Kent Lloyd, DVM, PhD. (School of Veterinary University of California, USA); Terry Magnuson, Ph.D. (UNC-Chapel Hill, USA); Jennifer A. Marshall Graves, Ph.D. (The Australian National University, Australia); Diane Mathis, Ph.D. (Joslin Diabetes Center Harvard Medical School, USA); Mark Moore, Ph.D. (International Mouse Phenotyping Consortium, UK); Ardem Patapoutian, Ph.D. (The Scripps Research Institute, USA); Oliver Ryder, Ph.D. (Institute for Conservation Research, USA); David Threadgill, Ph.D. (The University of North Carolina, USA); Inder Verma, Ph.D. (The Salk Institute, USA)

In addition platform presentations will be selected from contributed abstracts, each presenter will have approximately 15 minutes to present their paper including questions/discussion time. Poster sessions will also take place during the program which will enable all interested parties to present their work.

speaker-picDavid Adams, Ph.D. (Wellcome Trust Sanger Institute, UK);
David graduated from the University of Technology, Sydney with a B.Sc (Hons) in Biomedical science in 1996 having specialized in pathology, haematology and molecular genetics. He worked in clinical diagnostic laboratories before moving to the Department of Physiology at the University of Sydney to undertake a PhD with Prof. Brian Morris which was completed in 2001. David then moved to the Wellcome Trust Sanger Institute in late 2001 to start a postdoc with Prof. Allan Bradley. In Allan Bradley's lab David developed an interest in cancer genetics, refined technologies for modifying the mouse genome, and developed a large number of mouse models to study disease gene function. In 2006 David was awarded a CR-UK Career Development fellowship and joined the faculty of the Sanger Institute. As a faculty member David is performing forward genetic screens to uncover cancer genes and cancer pathways and is also leading a programme to use next generation sequencing to decode the genomes of 17 commonly used mouse strains. In addition to being a faculty member at the Sanger Institute David is also adjunct-faculty at the Cambridge Cancer Research Institute.

speaker-picSteve Barthold, DVM, Ph.D. (School of Veterinary Medicine University of California, USA);
Dr. Barthold, Distinguished Professor of Veterinary and Medical Pathology at the University of California Davis, is Director of the UC Davis Center for Comparative Medicine, a research and teaching center that is co-sponsored by the Schools of Veterinary Medicine and Medicine.

Dr. Barthold received his B.S. and D.V.M. from the University of California, Davis in 1967 and 1969. He served as a Captain in the U.S. Army Veterinary Corps at the U.S. Army Research Institute of Environmental Medicine, Natick, MA from 1969 through 1971. He sought further training in experimental and comparative pathology at the University of Wisconsin, Madison, and received his M.S. and Ph.D. in 1973 and 1974.  In 1974, he was appointed Assistant Professor of Comparative Medicine at the Yale School of Medicine, with subsequent promotion to Full Professor in 1989. He earned Diplomate status in the American College of Veterinary Pathologists in 1976. He moved to the University of California, Davis in 1997. Dr. Barthold was elected to the National Academies Institute of Medicine (IOM) in 2001, and is recipient of several career awards, including the American Association for Laboratory Animal Science Nathan R. Brewer Award for Career Excellence in Research, University of California Alumni Achievement Award, Francis Schofield Medal from the Ontario Veterinary College, Pfizer Research Award, American Veterinary Medical Association’s Charles River Award, and Honorary Diplomate status in the American College of Laboratory Animal Medicine. His professional specialty is infectious diseases of laboratory rodents and biology of the laboratory mouse. He has served on numerous national scientific advisory and review committees, and is currently Chairman of the National Academies Institute for Laboratory Animal Research (ILAR) Council. His research career has been funded continuously by the NIH for over 30 years, including a primary focus on Lyme borreliosis. He has published over 300 peer-reviewed articles, chapters and books.

speakerpicBruce Beutler, M.D. (The Scripps Research Institute, USA);
Dr. Bruce Beutler received his M.D. degree at the University of Chicago in 1981, but has worked as an immunologist for the past 26 years.  He isolated mouse tumor necrosis factor (TNF), and discovered its inflammatory effects.  He was the first to use anti-TNF antibodies to block inflammation in animals, and invented recombinant inhibitors of TNF activity, now widely used in clinical medicine.  He then employed TNF production as a phenotypic endpoint to map and positionally clone the Lps locus of mice.  Mutations at this locus had long been known to prevent responses to lipopolysaccharide (LPS), and to enhance susceptibility to Gram-negative infection.  Beutler’s work established Toll-like receptors as the principal sensors of the innate immune system, discriminating self from non-self.  It also revealed their importance as proximal initiators of systemic inflammatory diseases.  These discoveries opened a vibrant new field of research in immunology.  Now Chairman of the Department of Genetics at the Scripps Research Institute in La Jolla, CA, Beutler has applied ENU mutagenesis to create more than 100 variant phenotypes related to the innate immune response, and to host resistance in the broadest sense.

Beutler is a member of the National Academy of Sciences (USA) and the Institute of Medicine (USA).  His work has been recognized by numerous awards, including the Robert Koch Prize (2004), the William B. Coley Award (2006), the Gran Prix Charles-Leopold-Mayer (2006), the Balzan Prize (2007), The Albany Medical Center Prize (2009), and other honors.

speakerpicSteve Brown, Ph.D. (Harwell Science and Innovation Campus, UK);
Steve Brown is Director of the Medical Research Council’s Mammalian Genetics Unit at Harwell, Oxfordshire, UK. He did his PhD at Cambridge University and before he joined the MRC, he was Professor of Genetics at Imperial College, London. His research interests cover mouse functional genomics, including the use of mouse mutagenesis and comparative genomic analysis to study the genetic basis of disease and to develop pre-clinical disease models. A particular focus has been the use of mouse models to study the molecular basis of genetic deafness. He is a fellow of the Academy of Medical Sciences, a member of the European Molecular Biology Organisation and has authored over 200 scientific publications.

speakerpicCatherine Dulac, Ph.D. (Harvard University, USA);
Catherine Dulac is an Investigator at the Howard Hughes Medical Institute, is the Higgins Professor of Molecular and Cellular Biology and Department Chair at Harvard University. She obtained her Ph.D. from the University of Paris for work done with Nicole Le Douarin on the developmental mechanisms of neural crest cell differentiation. As a postdoctoral fellow with Richard Axel at Columbia University, she identified the first candidate gene family encoding mammalian pheromone receptors. Her laboratory is interested in the molecular organization of neural circuits underlying behavior in mammals. She was elected a fellow of the American Academy of Arts and Sciences in 2004, received the 2006 Richard Lounsbery Award, and was inducted into the French Academy of Sciences in 2007.

speakerpicJanan Eppig, Ph.D. (The Jackson Laboratory, USA);

Janan Eppig received her B.S. in Mathematics from the University of Washington, Seattle, and her Ph.D. in Genetics from the University of Maine. Her research interests include comparative genomics, genome organization, model systems for human disease, bioinformatics, and the development of database resources, including semantic standards for annotation and data sharing. She is currently a Professor at The Jackson Laboratory and heads the Mouse Genome Database (MGD), the core component the Mouse Genome Informatics Database Resource (MGI). She also directs the International Mouse Strain Resource (IMSR) and the Mouse Tumor Biology Dabatase (MTB); is co-investigator for the Gene Expression Database (GXD) and the Knockout Mouse Data Coordination Center (KOMP-DCC); and is a participating partner in the International Mouse Knockout Consortium Data Center (IDCC) and the EU project on Coordination of Resources for Conditional Expression of Mutated Mouse Alleles (CREATE).

Ron Evans, Ph.D. (The Salk Institute, USA);

speakerpicColin Fletcher, PhD (National Human Genome Research Institute, USA)

Colin Fletcher received his Ph.D. from The Rockefeller University in 1989 in the field of Biochemistry and Molecular Biology. His thesis work included the purification and characterization of the transcription factor Oct1. He switched into the field of mouse genetics with an interest in cerebellar development and function. He was a postdoc in the lab of Nat Heintz before moving to the lab of Neal Copeland and Nancy Jenkins in 1992. In 2000 he became a Principal Investigator at the Genomics Institute of the Novartis Research Foundation in San Diego where he oversaw the design and implementation of a large-scale mouse ENU mutagenesis screen. In 2006 he moved to the National Human Genome Research Institute at NIH where he is a program director supervising the mouse knockout project (KOMP). Dr. Fletcher has published over 50 peer-reviewed articles and book chapters.

speakerpicChris Goodnow, Ph.D. (Australian Cancer Research Foundation Genetics Laboratory and Medical Genome Centre, John Curtin School of Medical Research, Australian National University, Australia);

C Goodnow has illuminated the mechanism of immunological self-tolerance through innovative integration of mouse molecular genetics with cellular immunology.  His discoveries have changed our concepts of how self-tolerance is acquired and autoimmune diseases are prevented, by revealing that self-reactive lymphocytes are controlled by a series of mechanisms serving as checkpoints at each step along the process of antibody formation.  He has elucidated how these checkpoints achieve self-nonself discrimination, through an ability of antigen receptors to switch between signalling lymphocyte proliferation or triggering tolerance responses via qualitative changes in the intracellular second messengers elicited.

After a BSc(Vet) and Veterinary Medicine degree at the University of Sydney, Goodnow trained in molecular and cellular immunology at Stanford University with Mark M Davis, at the Walter and Eliza Hall Institute with Sir Gustav Nossal, and at the University of Sydney with Antony Basten. From 1990-1997, Goodnow headed a laboratory at Stanford University Medical School as an Assistant Investigator of the Howard Hughes Medical Institute.  Since 1997, he has been Professor of Immunology and Genetics at the John Curtin School of Medical Research at The Australian National University, and is currently Head of the Immunology Program.  Goodnow was the Founding Director of the Australian Phenomics Facility – a major national research facility for mouse molecular genetics.  In translating his scientific expertise, Goodnow served on the founding scientific advisory board of Illumina Inc – now a leading genetic analysis technology company – and was founder and chief scientific officer for Phenomix Corp, a private biotechnology company with treatments for diabetes and infection in clinical development.

Goodnow has authored many papers in Nature, Science and Cell, and serves on the editorial advisory boards of the Journal of Experimental Medicine, Immunity, Genome Biology, and Mammalian Genome.  His honours and awards include the University Medal from Sydney University, Assistant Investigator of the Howard Hughes Medical Institute, Searle Scholar, American Association of Immunologists/Pharmingen Investigator Award, the Gottschalk Medal of the Australian Academy of Science, Commonwealth Centenary Medal, Fellow of the Australian Academy of Science, Federation Fellow of the Australian Research Council, Fellow of the Royal Society London, and the Australian Health Minister’s Prize for Excellence in Medical Research.

speakerpicKent Lloyd, DVM, PhD. (School of Veterinary University of California, USA);

Kent Lloyd, DVM, PhD, is a Professor and Associate Dean of Research at the School of Veterinary Medicine, University of California, Davis. Dr. Lloyd received his BA from UCSD in 1979, and his DVM from UCD in 1983. He received clinical training in large animal medicine and surgery at the University of Pennsylvania and at UC Davis.  In 1992, Dr. Lloyd received his PhD in physiology under the mentorship of Dr’s. Jared Diamond and John H. Walsh at UCLA. He was appointed assistant professor in the School of Medicine at UCLA where he established his NIH-funded laboratory studying enterogastric mechanisms of action. Recognizing the utility of genetically-altered mice for the study of gastroenterology, he pursued research on conditional mutagenesis while a visiting scientist at the European Molecular Biology Laboratory in Heidelberg, Germany.  In 1997, Dr. Lloyd was recruited to UC Davis where today he is a teacher, researcher, and administrator.  He currently heads the NIH-sponsored Mutant Mouse Regional Resource Center (MMRRC) and the Knockout Mouse Project (KOMP) Repository, and is Director of the UC Davis Mouse Biology Program.

speakerpicTerry Magnuson, Ph.D. (UNC-Chapel Hill, USA);
Magnuson was recruited to Carolina in 2000 as founding chair of the Department of Genetics and director of the newly established Carolina Center for Genome Sciences. He also created the Cancer Genetics Program in the UNC Lineberger Comprehensive Cancer Center. A founding member of the International Mammalian Genome Society, Magnuson served on the external advisory committee for the Mouse Genome Database at the Jackson Laboratory in Bar Harbor, Maine, and is currently the Chair of the Jackson Laboratory Board of Scientific Overseers. He served on the board of directors of the Society for Developmental Biology and also for the Genetics Society of America. He was appointed by the National Academy of Sciences to help establish guidelines for work with human embryonic stem cells. He was elected to the American Academy of Sciences in 2007 and the AAAS in 2009. The work in the Magnuson lab focuses on the role of mammalian genes in unique epigenetic phenomena such as genomic imprinting and X-chromosome inactivation. The lab also studies the tumor suppressor role of the BAF/PBAF chromatin remodeling complexes and has developed a novel genome-wide mutagenesis strategy.

speakerpicJennifer A. Marshall Graves, Ph.D. (The Australian National University, Australia);

BSc Hons and MSc, University of Adelaide 1963, 1967
PhD in Molecular Biology, University of California, Berkeley 1971

Professor Jenny Graves works on the genetics and genomics of Australian animals – kangaroos and platypus are a specialty, but snakes and emus, devils (Tasmanian) and dragons (lizards) are becoming important. Her group uses the distant relationship of Australian mammals from humans to understand how genes and chromosomes evolved and how they work in all mammals including humans. Her laboratory is famous for using this unique perspective to explore the origin, function and (dismal) fate of human sex chromosomes, and even to discover novel human genes.

Jenny has produced three books and more than 350 research articles.

Jenny heads the Comparative Genomics Research group in the Research School of Biology at ANU, and directs the multinode ARC Centre of Excellence in Kangaroo Genomics.

Jenny has received a number of honours and awards, including the Macfarlane Burnet medal in 2006. She is a Fellow of the Australian Academy of Science and Foreign Secretary of the Academy, and is 2006 L’Oreal-UNESCO Laureate.

mathisDiane Mathis, Ph.D. (Joslin Diabetes Center Harvard Medical School, USA);
Dr. Diane Mathis obtained a Ph.D. from the University of Rochester, and performed postdoctoral studies at the Laboratoire de Génétique Moléculaire des Eucaryotes in Strasbourg, France and at Stanford University Medical Center. She returned to France at the end of 1983, establishing a laboratory at the Institut de Genetique et de Biologie Moleculaire et Cellulaire (LGME) [later the Institut de Genetique et de Biologie Moleculare et Cellulaire  (IGBMC)] in Strasbourg, in conjunction with Dr. Christophe Benoist. The lab moved to the Joslin Diabetes Center, Boston, MA at the end of 1999. Through 2008, Dr. Mathis was a Professor of Medicine at Brigham and Women’s Hospital and Harvard Medical School, and an Associate Research Director and Head of the Section on Immunology and Immunogenetics at Joslin, where she held the William T. Young Chair in Diabetes Research. In early 2009, the lab moved to the Pathology Department at Harvard Medical School. Dr Mathis is currently Professor of Pathology at HMS. She is also Director of the JDRF Center on Immunological Tolerance in Type-1 Diabetes at HMS, a Principal Faculty Member at the Harvard Stem Cell Institute and an Associate Faculty Member of The Broad Institute. Dr. Mathis was elected to the US National Academy of Sciences in 2003 and to the German Academy in 2007. The lab works in the fields of T cell differentiation and autoimmunity.

speaker-picMark Moore, Ph.D. (International Mouse Phenotyping Consortium, UK);
Dr. Mark Moore, Ph.D. received his Ph.D. in Molecular Biology and Immunology from Brandeis University in 1987. His work in the lab of Dr. Erik Selsing focused on antibody gene recombination and using transgenic mice to study the immune system. He was a post-doctoral fellow in the laboratory of Dr. Michael Bevan at the Scripps Research Institute from 1987-1990, where he worked on antigen processing and presentation, T-cell development, and began work on gene knockout mice. Dr. Moore then moved to Genentech where he developed gene knockout mice for a variety of projects as both fundamental research tools and part of the product development validation program. In, 1997 he became a co-founder and CSO of Deltagen, which created over 1000 mouse gene knockouts in a variety of disease indications to develop novel drug targets. He built and developed the research groups that created Deltabase, a phenotype database of knockout mice that delivered functionally validated targets for drug discovery in the areas of neurobiology, immunology, diabetes, pain and metabolic disorders. Dr. Moore has been advising the NIH on the development and direction of the KOMP program since 2004 and recently accepted the role of Program Manager for the International Mouse Phenotyping Consortium (IMPC).

speaker-picArdem Patapoutian, Ph.D. (The Scripps Research Institute, USA);
Ardem Patapoutian received his B.Sc. in 1990 from the University of California, Los Angeles, USA, and his Ph.D. in 1996 from the California Institute of Technology, USA, working with Dr Barbara Wold. He was a Damon Runyon postdoctoral fellow with Dr Louis Reichardt at the University of California, San Francisco. He has held a joint appointment at The Scripps Research Institute (TSRI) and the Genomics Institute of The Novartis Research Foundation (GNF) since 2000. Currently, he is a professor in the Department of Cell Biology at TSRI, affiliated with the Harold Dorris Neurological Institute, and Director of Discovery Research at GNF. He was awarded the Society of Neuroscience's Young Investigator Award (2006), a Damon Runyon Scholar Award (2003–2006) and a Basil O'Connor Scholar Award (2001–2003). Patapoutian's major research interest is in the molecular understanding of somatosensory neuron function.

RyderOliver Ryder, Ph.D. (Institute for Conservation Research, USA).
Dr. Oliver A. Ryder holds the Kleberg Chair and is Director of Genetics for San Diego Zoo’s Institute for Conservation Research and is an Adjunct Professor of Biology at U.C. San Diego. His laboratory has conducted studies of systematics and evolution of vertebrate taxa, including Carnivora, Perissodactyla and Artiodactyla. He oversees San Diego Zoo’s Frozen Zoo®, a unique repository of biomaterials that includes frozen early-passage diploid fibroblast cultures from more than 8,700 individuals, comprising more than 800 taxa of mammals, birds, reptiles and amphibians. He is an organizer, with David Haussler and Steve O’Brien of the Genome 10K project, laying the groundwork for an eventual large-scale sequencing and analysis project of vertebrate genomes.

RyderDavid Threadgill, Ph.D. (The University of North Carolina, USA);
David Threadgill, PhD is Professor and Head of Genetics at North Carolina State University and Research Professor at the University of North Carolina at Chapel Hill. HIs research focuses on using mice as to model human health and disease with a particular focus on colon cancer and environmental exposure. He co-organized a planning workshop at the 15th Annual International Mammalian Genome Conference in 2001 to present a plan for a new multi-parental mouse recombinant inbred resource optimally designed for quantitative and systems genetics analysis in mice. This lead to the design and implementation of the Collaborative Cross genetic reference population.

vermaInder Verma, Ph.D. (The Salk Institute for Biological Sciences, USA)
Inder M. Verma is a professor in the Laboratory of Genetics and holds the Mark Jacobs Chair in Exemplary Life Science and American Cancer Society Professor of Molecular Biology. He received his PhD degree from the Weizmann Institute of Science, Rehovot, Israel in 1971, completed postdoctoral training with David Baltimore at Massachusetts Institute of Technology in 1974, and has been with the Salk Institute as Assistant Professor, Associate Professor and now Professor from 1974 to present. Dr. Verma is one of the world's leading authorities on the development of viruses for gene therapy vectors and uses genetically engineered viruses to insert new genes into cells that can then be returned to the body, where they produce the essential protein whose absence causes disease. Dr. Verma and Salk colleagues developed a gene therapy vector, based on a stripped-down version of HIV that can deliver genes to nondividing cells, which constitute the majority of the cells in our bodies. They have used this vector successfully to deliver the clotting factor gene to laboratory animals and to transfer a therapeutic gene to retinal cells to mice with an inborn deficiency. Dr. Verma's group is also studying two genes implicated in familial breast cancer, BRCA1 and BRCA2, and recently demonstrated that their action is linked to the cell's division cycle and that BRCA1 regulates gene activity.

Dr. Verma has been on the editorial boards of a number of international scientific journals, including serving as editor-in-chief of Molecular Therapy, a journal specializing in gene therapy.  He is also handling editor for the Proceedings of the National Academy of Sciences (USA).  Dr. Verma’s scientific contributions have been recognized by a number of honors, including one of 25 lifetime American Cancer Society Professorships (1990), an Outstanding Investigator Award from the NIH (1988), membership in the Third World Academy of Sciences (1995), the National Academy of Sciences, India (1997), the National Academy of Sciences, USA (1997), the Institute of Medicine (1999), a Fellow of the American Academy of Arts and Sciences (2000), an Associate Member of the European Molecular Biology Organization, EMBO (1998) and election to the American Philosophical Society (2006).

< Back to top

Conference organisers: In Conference Ltd. www.in-conference.org.uk